A Phase IIA Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus in Men with Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer

• Conditions: Metastatic prostate cancer; MedDRA version: 13.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2008-000422-39-GB
• Lead Sponsor: Merck Sharp & Dohme Corp.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11-24
• Last Update Posted: 12 June 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 180

Inclusion Criteria

1. Patient has histologically confirmed adenocarcinomas of the prostate.
2. Archival pathological material is available for submission to central laboratory.
3. Patient has evidence of metastatic disease at protocol entry or at the time of prior hormonal manipulation, determined radiographically by the presence of at least 2 bone scan lesions consistent with metastases or abdominal/pelvic lymph nodes > 2 cm on longest axial measurement. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or magnetic resonance imaging (MRI).
4. Patient has evidence of disease progression despite castrate levels of testosterone (< 50 ng/dl) following orchiectomy or during therapy with a luteinizing hormone releasing hormone (LHRH) agonist or antagonist (with or without an anti-androgen). Evidence of disease progression must include one of the following:
a) Levels of PSA are defined as increasing when at least three measurements, obtained at least one week apart, show increases. (The minimum starting PSA level for trial entry is 7 ng/mL except during safety lead-in.)
b) Progressive lymph node disease is defined per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The longest diameter of any node must measure at least 2 cm on spiral computed tomography (CT) to qualify as a target lesion.
c) Worsening bone scan is defined as an increase of 2 or more lesions from a previous bone scan. Solitary or ambiguous bone lesions should be confirmed with plain radiographs or MRI.
5. Patient has a PSA > 7 ng/ml (during safety lead-in only patients meeting other eligibility criteria may be enrolled with any PSA value).
6. aminimum of four weeks has elapsed between prior surgery or radiotherapy (limited to no more than 25% of the bone marrow) and enrollment.
7. Patient maintains therapy with a LHRH agonist or antagonist for the duration of the study, or has undergone bilateral orchiectomy.
8. Patient has performance status =1 on ECOG performance scale.
9. Patient is =18 years and gives written consent.
10. Paitnets who are not surgically steril are required to use a reliable method of contraception from time of screening until 30 days after the last dose of study drug.
11. Patient has adequate organ function.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patient has received bicalutamide, flutamide, cyproterone or nilutamide within the past 12 months except for use of less than 30 days duration during the initiation of LHRH analog therapy (during safety lead-in only patients meeting other eligibility criteria may be enrolled as long as they have not received any anti-androgen withihn the past 4 weeks).
2. Patient has received prior chemotherapy for metastatic prostate cancer.
3. Patient has previously received rapamycin or rapamycin analogs, including ridaforolimus, temsirolimus, or everolimus or is receiving corticosteroids administered at doses greater than those used for normal replacement therapy.
4. Patient is receiving an opioid or narcotic analgesic prescribed for pain due to prostate cancer.
5. In the opinion of the investigator, the patient has pain related to metastatic prostate cancer that warrants the initiation of chemotherapy.
6. Patient has a history of prior malignancy including primary central nervous system tumour, with the following exceptions: basal cell carcinoma of the skin; or any patient who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk of recurrence by his treating physician.
7.Patient has any visceral matastatic disease including malignant pleural effusions or ascites, current or previuosly treated epidural disease, active or treated CNS metastases and or carcinomatous meningitis. Exception: patients with treated epidural lesions and no other epidural progression are eligible for study entry.
8. Patient has known hypersensitivity to macrolide antibotics 9i.e. clarithomycin, erythromycin, or azythromycin); or bicalutamide.
9. Patient has NYHA Class III or IV congestive heart failure or any other significant history of cardiac disease including: myocardial infarction within the last 6 months; ventricular arrhythmia or acute congestive heart failure within the last 3 months; uncontrolled angina or uncontrolled hypertension.
10. Patient has newly diagnosed (within 3 months before enrollment) or poorly controlled Type 1 or 2 diabetes.
11. Patient has an active infection requiring prescribed intervention.
12. Patient is known to be human immunodeficiency virus (HIV) positive.
13. Patient has a known history of Hepatitis B or C.
14. Patient has known psychiatric or substnace abuse disorders that would interfere with cooperation with the requirements of the trial.
15. Patient is at the time of signing informed consent a regular user ( including recreational use) of any illicit drugs or has a recent history (within the last year) or drug or alcohol use.
16. Patient has not adequately recovered from any prior surgical procedure or as undergone any major surgical procedure within 2 weeks prior to the first dose of study drug (patients having undergone recent placement of a central venous access port will be considered eligible if they have fully recovered).
17. Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study or interfere with the patient's participation for the full duration of the study, or it is not in the best interest of the patient to participate.
18. Patient has a requirement for concurrent treatment with medications that are inducers or inhibitors of cytochrome P450 3A (CYP3A). Patients should be off these medications for at least 2 weeks prior to the first dose of ridaforolimus. Concomitant medi

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified